Q1 2025 · 13F-HR
ACORN CAPITAL ADVISORS, LLCholdings as filed
Filed 2025-05-15 · accession 0001636587-25-000017
$143.7M
Reported value
22
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $27.7M | 19.3% | 1,131,501 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $16.8M | 11.7% | 1,516,303 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $14.3M | 9.97% | 3,235,387 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $13.5M | 9.39% | 2,144,844 | Common | SOLE |
| 137404109 | CADL | CANDEL THERAPEUTICS INC | $12.2M | 8.46% | 2,152,252 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $11.7M | 8.12% | 3,940,052 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS | $8.4M | 5.83% | 643,382 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $5.5M | 3.79% | 1,279,800 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $5.4M | 3.79% | 1,971,264 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $4.7M | 3.25% | 734,394 | Common | SOLE |
| 14147L108 | CRDF | CARDIF ONCOLOGY INC | $4.5M | 3.15% | 1,442,308 | Common | SOLE |
| 68404V209 | OPTNUSD | OPTINOSE INC | $3.9M | 2.70% | 422,814 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $2.7M | 1.90% | 452,110 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $2.0M | 1.41% | 1,139,363 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $1.8M | 1.22% | 7,310,650 | Common | SOLE |
| G63365103 | MURA | MURAL ONCOLOGY PLC | $1.6M | 1.11% | 1,269,715 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $1.5M | 1.01% | 590,508 | Common | SOLE |
| 09077B104 | BCABGBP | BIOATLA INC | $1.4M | 0.98% | 4,032,046 | Common | SOLE |
| 746964105 | QTTB | Q32 BIO INC. | $1.3M | 0.92% | 803,425 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $1.2M | 0.86% | 785,938 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $856,513 | 0.60% | 199,189 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $822,632 | 0.57% | 405,237 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.